摘要
目的:体内外研究TKH-03对ABCB1介导的卵巢癌耐药的影响及作用机制,探讨TKH-03能否作为耐药逆转剂。方法:采用细胞克隆实验检测TKH-03在体外对A2780T细胞的克隆、增殖影响。通过Ki-67免疫组化染色观察TKH-03在体内对A2780T细胞的影响,同时进行初步安全性评价。分子对接分析,探究与维拉帕米相比,TKH-03与ABCB1分子模型的相互作用情况。结果:细胞克隆实验显示,TKH-03与紫杉醇联用对A2780T细胞的体外增殖能力具有较强的抑制作用。体内抗肿瘤研究显示,TKH-03能增强紫杉醇介导的肿瘤组织细胞凋亡,差异有统计学意义(P<0.01)。TKH-03联合紫杉醇对荷瘤鼠的肝肾功能无明显影响,未发生明显毒副作用。分子对接结果显示,TKH-03与ABCB1通过氢键和疏水作用紧密结合。与ABCB1底物维拉帕米相比,TKH-03与ABCB1的结合更稳定。结论:TKH-03在体内外逆转A2780T细胞对紫杉醇的耐药性,且与紫杉醇联用具有良好的安全性,其逆转耐药机制与ABCB1靶点有关。
Objective:To study the effect of TKH-03 on ABCB1-mediated ovarian cancer resistance and its mechanism in vitro and in vivo,and to explore whether TKH-03 can be used as a drug resistance reversal agent.Methods:Cell cloning experiment was conducted to investigate the effect of TKH-03 on the cloning and proliferation of A2780T in vitro.Ki-67 immunohistochemical staining was used to observe the effect of TKH-03 on A2780T cells in vivo,and preliminary safety evaluation was conducted at the same time.Molecular docking analysis was conducted to explore the interaction between TKH-03 and ABCB1 molecular model compared with commercially available verapamil.Results:The cell cloning experiment showed that the combination of TKH-03 and paclitaxel had a strong inhibitory effect on the proliferation of A2780T cells in vitro.In vivo anti-tumor studies showed that TKH-03 could enhance the apoptosis of tumor tissue cells mediated by paclitaxel,and there was a significant difference.The indexes of liver and kidney function were all within the normal range,and there was no significant difference.No obvious toxic or side effects occurred.Molecular docking results showed that TKH-03 was closely bound to ABCB1 through hydrogen bonding and hydrophobic interaction.Compared with verapamil,the substrate of ABCB1,the binding of TKH-03 to ABCB1 is more stable.Conclusion:TKH-03 can reverse paclitaxel resistance in A2780T cells in vitro and in vivo,and has good safety when combined with paclitaxel.The mechanism of reversing resistance is related to ABCB1.
作者
何丽
龚照林
黄璐
廖晓燕
林永红
He Li;Gong Zhaolin;Huang Lu(Chengdu Women's and Children's Central Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610000)
出处
《现代妇产科进展》
北大核心
2023年第8期586-590,594,共6页
Progress in Obstetrics and Gynecology
基金
成都市科技局重点研发支撑计划(No:2021-YF05-02004-SN)。